Today: 29 April 2026
Nokia stock steadies before U.S. open after Hisense patent deal ends litigation
8 January 2026
1 min read

Nokia stock steadies before U.S. open after Hisense patent deal ends litigation

NEW YORK, Jan 8, 2026, 08:12 EST — Premarket

Nokia Oyj said on Thursday it signed a multi-year patent licence with Hisense covering the use of Nokia’s video technologies in Hisense televisions, ending all patent-related litigation between the companies. Nokia’s U.S.-listed shares were indicated around $6.80 in premarket trading. “We are delighted to have reached an agreement with Hisense,” Susanna Martikainen, Nokia’s chief licensing officer for wireless technologies, said in a statement. Nokia Corporation | Nokia+1

The deal is a reminder that Nokia’s patent licensing arm can still throw off cash even as its core network business tracks telecom spending. It also removes a legal headache, which can matter for a stock that trades on small changes in margin expectations.

On Wednesday, Kepler Cheuvreux upgraded Nokia to “buy” from “hold” and raised its target price to 6.60 euros, saying a recent pullback offered a better entry point. The broker said it expects a recovery in sales, margins and cash flow over the coming years. Investing.com

Nokia’s American depositary receipts (ADRs) — U.S.-traded shares that track the foreign stock — jumped 4.95% to $6.79 in the prior session, snapping a two-day losing streak. Volume hit 52.7 million shares, and the stock is still about 17% below its 52-week high of $8.19 set on Oct. 28, MarketWatch data showed.

Separately, Telit Cinterion said it is working with Nokia on mission-critical connectivity and in-network computing for heavy industries, with demonstrations planned at CES 2026 in Las Vegas. “This collaboration marks a pivotal moment for mission-critical industries,” said Lelio di Martino, general manager for Nokia’s Cognitive Digital Mine, according to the release. Telit Cinterion

“In-network” computing is industry shorthand for processing data close to the machine, rather than sending it back to a distant cloud server. The pitch is simple: keep systems running when links get patchy.

One catch: Nokia and Hisense did not disclose financial terms. That leaves traders guessing how quickly any royalty income shows up, and how much of it is already baked into forecasts.

Stock Market Today

  • Peoples Bancorp (PEBO) Sees Share Price Momentum Amid Valuation Debate
    April 29, 2026, 9:20 AM EDT. Peoples Bancorp (PEBO) has gained investor focus following a robust share price rise, closing at $34.92. The Ohio-based regional bank, generating $424 million in annual revenue and $110 million in net income, holds a market value near $1.23 billion. Its recent returns include a 7.5% rise over one month and 15.8% year-to-date, with a 27.2% total shareholder return in one year, signaling growing momentum. Analysts place its intrinsic value around $37.17, about 6% above the current price, suggesting a modest undervaluation. Growth drivers include loan expansion, deposit growth, and strategic capital management. However, risks from credit costs and funding pressures may affect margins. Investors are advised to weigh these factors when considering PEBO amid a competitive community banking landscape.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Uber stock gets a CES jolt as Lucid-Nuro robotaxi plan takes shape
Previous Story

Uber stock gets a CES jolt as Lucid-Nuro robotaxi plan takes shape

Ondas stock slips after SEC filing tees up more shares for resale in Sentry deal
Next Story

Ondas stock slips after SEC filing tees up more shares for resale in Sentry deal

Go toTop